Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ludaterone acetate - ASKA Pharmaceutical

Next Previous
X
Search
Drug Profile

Ludaterone acetate - ASKA Pharmaceutical

Alternative Names: AKP-009

Latest Information Update: 26 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ASKA Pharmaceutical
  • Class Urologics
  • Mechanism of Action Androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Benign prostatic hyperplasia

Most Recent Events

  • 30 Nov 2022 Ludaterone acetate is still in phase IIa trial for benign prostate hyperplasia in Japan (ASKA Pharmaceutical pipeline, November 2022) (JapicCTI-195084)
  • 29 Sep 2022 ASKA Pharmaceutical completes a phase II trial in Benign prostatic hyperplasia in Japan (PO) prior to September 2022 ((JapicCTI-195084) (ASKA Pharmaceutical pipeline, September 2022)
  • 30 Sep 2020 ASKA Pharmaceuticals and Kyorin Pharmaceutical agree to co-promote and co-develop AKP 009 in Japan for Benign prostatic hyperplasia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top